Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated

被引:102
作者
Guyatt, G [1 ]
Weaver, B
Cronin, L
Dooley, JA
Azziz, R
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[2] McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada
[3] Pfizer Ltd, Tadworth, Surrey, England
[4] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
关键词
quality of life; health-related quality of life; polycystic ovary syndrome; questionnaire;
D O I
10.1016/j.jclinepi.2003.10.018
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: We examined the measurement properties of a questionnaire (PCOSQ) measuring health-related quality of life (HRQOL) in women with the polycystic ovary syndrome (PCOS). Study Design: This multicenter prospective randomized placebo-controlled blinded study enrolled 393 patients with PCOS at tertiary care sites. Participants were randomized to placebo or troglitazone (150 mg/d. 300 mg/d. or 600 mg/d). At baseline (n = 393) and after 44 weeks of treatment (n = 284) the proportion of normal menstrual cycles, the free testosterone (T) level. four objective measures of facial hair growth (hair density and hair growth rate by photography. and hair diameter and hair growth rate using plucked hairs). and a subjective assessment of the degree of hirsutism. the modified Ferriman-Gallwey (F-G) score. were determined. At both visits. patients also completed the PCOSQ. Since the trial was conducted, troglitazone has been removed from the market because of toxic effects. The PCOSQ includes 26 questions (items) that address five areas of concerti (domains), including emotions, body, hair, body weight fertility. and menstruation rated on a seven-point scales in which lower scores denote higher degrees of patient concern and a lower HRQOL. Results: Cronbach's alpha was >0.7 for four of five domains. Factor analysis provided moderate to strong support for the five-domain structure of the PCOSQ. Cross-sectional correlations were weak with all measures but the F-G score and hair growth (r = -.46. P <.01). The change in the F-G score showed a statistically significant (P <.01) correlation with changes in PCOSQ hair growth (r= -.22). weight (r 17), infertility (r = -.20), and menstruation (r = -.20). Changes in the proportion of normal menstrual cycles correlated with change in the infertility domain (r =.14, P <.03) and with the change in the menstruation domain (r =.31. P < -001). The PCOSQ proved as responsive as the F-G. and more responsive than the objective measures of hair growth. to effects of trogliazone. Conclusions: Our data provides some support for the discriminative and longitudinal validity% and appreciable support for the responsiveness, of the PCOSQ. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1279 / 1287
页数:9
相关论文
共 35 条
[1]  
Andrew F., 1976, SOCIAL INDICATORS WE
[2]   A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain [J].
Asunción, M ;
Calvo, RM ;
San Millán, JL ;
Sancho, J ;
Avila, S ;
Escobar-Morreale, HF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2434-2438
[3]   Troglitazone use in polycystic ovary syndrome - Response [J].
Azziz, R ;
Ehrmann, D ;
Legro, RS ;
Whitcomb, R ;
Hanley, R ;
Fereshtian, AG ;
O'Keefe, M ;
Ghazzi, MN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :5090-5091
[4]   Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial [J].
Azziz, R ;
Ehrmann, D ;
Legro, RS ;
Whitcomb, RW ;
Hanley, R ;
Fereshetian, AG ;
O'Keefe, M ;
Ghazzi, MN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1626-1632
[5]   THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[6]   Cronbach's alpha [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 1997, 314 (7080) :572-572
[7]   VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE [J].
BRAZIER, JE ;
HARPER, R ;
JONES, NMB ;
OCATHAIN, A ;
THOMAS, KJ ;
USHERWOOD, T ;
WESTLAKE, L .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6846) :160-164
[8]   DOES ETHNICITY INFLUENCE THE PREVALENCE OF ADRENAL HYPERANDROGENISM AND INSULIN RESISTANCE IN POLYCYSTIC-OVARY-SYNDROME [J].
CARMINA, E ;
KOYAMA, T ;
CHANG, L ;
STANCZYK, FZ ;
LOBO, RA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (06) :1807-1812
[9]   HETEROGENEITY OF THE POLYCYSTIC OVARY SYNDROME - CLINICAL, ENDOCRINE AND ULTRASOUND FEATURES IN 556 PATIENTS [J].
CONWAY, GS ;
HONOUR, JW ;
JACOBS, HS .
CLINICAL ENDOCRINOLOGY, 1989, 30 (04) :459-470
[10]   Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS) [J].
Cronin, L ;
Guyatt, G ;
Griffith, L ;
Wong, E ;
Azziz, R ;
Futterweit, W ;
Cook, D ;
Dunaif, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :1976-1987